

# **PBPK for Regulators Workshop Summary - NAMS Roadmap (2023)**

## **In this guide**

### [In this guide](#)

1. [Cover - NAMS Roadmap \(2023\)](#)
2. [Executive summary - NAMS Roadmap \(2023\)](#)
3. [Introduction & Background NAMs Roadmap Draft Version 3 \(2023\)](#)
4. [What are NAMs and why is there a drive in the regulatory context? - NAMS Roadmap \(2023\)](#)
5. [Who are the UK FSA and the COT? - NAMS Roadmap \(2023\)](#)
6. [Worldwide perspectives on emerging technologies - NAMS Roadmap \(2023\)](#)
7. [UK Government cross cutting themes on NAMS, data and emerging technologies - NAMS Roadmap \(2023\)](#)
8. [Future Government cross themes - NAMS Roadmap \(2023\)](#)
9. [What have the FSA/COT done so far? - NAMS Roadmap \(2023\)](#)
10. [Exploring Dose Response \(EDR\) Workshop Summary - NAMS Roadmap \(2023\)](#)
11. [PBPK for Regulators Workshop Summary - NAMS Roadmap \(2023\)](#)
12. [The proposal: How does the FSA plan to integrate NAMs in the regulatory space? - NAMS Roadmap \(2023\)](#)
13. [The 7 Steps to Integration & Acceptance - NAMS Roadmap \(2023\)](#)
14. [Future Visions: The new normal chemical landscape - NAMS Roadmap \(2023\)](#)
15. [References - NAMS Roadmap \(2023\)](#)
16. [Abbreviations - NAMS Roadmap \(2023\)](#)
17. [Technical information - NAMS Roadmap \(2023\)](#)
18. [Acknowledgments - NAMS Roadmap \(2023\)](#)
19. [More information - NAMS Roadmap \(2023\)](#)

The UK FSA and the COT held a “PBPK for Regulators” workshop (December 2020) in a multidisciplinary setting with delegates from regulatory agencies, government bodies, academia and industry. The workshop provided a platform to

enable expert discussions and presentations on the application of PBPK to human health risk assessment in a regulatory context as well as potential future research.

### **Main overarching conclusions of the PBPK workshop:**

- a) PBPK modelling tools are applicable in the explored areas of use, and there is some expertise available for their utilisation.
- b) PBPK modelling offers opportunities from which to address questions for compounds that are otherwise not solvable.
- c) Widespread acceptance amongst regulatory bodies appears to be limited by lack of available in-house expertise.
- d) Familiarisation using real world case studies would help in developing more experts in the field and increasing acceptance.
- e) In a regulatory context, establishing fitness for purpose for the use of PBPK models require multi-partite discussion and harmonised guidance.
- f) Finally, PBPK modelling is part of the wider “new approach methodologies” for risk assessment.

### **Paving the way for a UK Roadmap-Development, Validation and Acceptance of New Approach Methodologies Workshop summary**

The UK FSA and the COT held a workshop that took place online over 2 days in October 2021. It had participation from industry, academics and regulators. The aim of the workshop was to receive insights, comments and input from a wide variety of stakeholders and industry, academia and government, on the roadmap so that it can be developed and a useful and engaging document produced, that is beneficial to more than just the FSA and COT. This included a range of scientists, policy and lawyers, and working in the international space and engaging with the public. Furthermore, there were discussions on what is holding the progress back including a range of areas such as law, economics, socio-technical barriers and regulatory frameworks.